Allos Therapeutics (ALTH) Presents FOLOTYN Data at EHA Congress

Allos Therapeutics, Inc. (Nasdaq: ALTH), will present the following data on FOLOTYN (pralatrexate injection) will be presented at two upcoming international medical conferences: the 16th Congress of the European Hematology Association (EHA) in London, England.

• Abstract Title: “Pralatrexate Selectively Induces Apoptosis and Synergizes with Bexarotene Through Up-Regulation of p53/Bax/PUMA in Cutaneous T-cell Lymphoma Cells”Abstract Number: 405Presentation Date/Time: Friday, June 10, 17:45-19:00 CET

Information regarding the presentations at ICML is as follows:

• Abstract Title: “Pralatrexate Reverses the Trend in Progressive Resistance with Successive Chemotherapy Regimens in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)”Abstract Number: 361Presentation Date/Time: Friday, June 17, 08:30-18:30 CET
  
  
• Abstract Title: “Pralatrexate, an Effective Single-Agent Second-Line Treatment Following Failure of Cyclophosphamide/Doxorubicin/Vincristine/Prednisone (CHOP) in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)”Abstract Number: 360Presentation Date/Time: Friday, June 17, 08:30-18:30 CET
  
  
• Abstract Title: “Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment (COMPLETE), a New International Treatment Registry”Abstract Number: 242Presentation Date/Time: Thursday, June 16, 08:30-18:30 CET

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Getty Realty discloses separation terms for departing accounting officer
• Simmons Bank chief data officer Lisa Hunter to retire
• Hertz Global amends voting agreement with CK Amarillo after lawsuit